What's behind Absci's revenue drop?

``` The deep research logic is organized as follows: Okay, let's tackle the question about Absci's revenue drop. First, I need to go through all the provided references to gather relevant data. The user is asking for the reasons behind the revenue miss, so I should focus on factors like financial performance, partnerships, R&D expenses, and market conditions. Looking at the references, the Q2 2025 earnings reports (Numbers 1, 2, 4, 7, 13, 17, 27, 28) all mention a significant revenue shortfall. The revenue was $600,000, which is way below the expected $1.39 million. That's a 56.83% miss. The main reasons cited are the absence of milestone payments from partnerships and high R&D costs. From the 10-Q report (Number 5), it's clear that partner program revenue dropped because of the timing of achieving milestones. This is a common issue for companies relying on partnerships. Also, the R&D expenses jumped to $20.5 million, up from $15.3 million YoY. This aggressive investment in internal programs like ABS-101 and ABS-201 is another key factor. The company did raise $64 million in July 2025 (Numbers 3, 14, 16, 26), which extended their cash runway to 2028. But the immediate impact on revenue isn't there yet. The pipeline is still in early stages, with ABS-101 in Phase 1 and ABS-201 preclinical. So, no revenue from these yet. Also, the market for AI-driven biotech is competitive. Competitors like Generate Biomedicines and Vilya (Numbers 11, 12) might be taking away potential partnerships or funding. The high burn rate and reliance on external funding could be making investors nervous, but the stock still went up after the earnings, showing some resilience (Numbers 1, 2, 6). Putting it all together, the main drivers are the lack of milestone payments, high R&D spending, early-stage pipeline, and competition. The company is betting on long-term AI-driven drug discovery, but the short-term financials are under pressure. Need to structure this into a clear analysis with tables and key points, making sure to cite the right references. ``` ### **Conclusion** Absci’s Q2 2025 revenue drop of 56.83% to $600,000 reflects a perfect storm of challenges: reliance on partnership milestones, escalating R&D costs, and early-stage pipeline execution risks. While the company extended its cash runway to 2028, the near-term financial pressure underscores the high-risk, high-reward nature of AI-driven biotech innovation. --- ### **Analysis** #### **1. Revenue Miss: Partnership-Driven Model Falters** Absci’s revenue heavily depends on milestone payments from collaborations, which were absent in Q2 2025. The company reported no new major partnerships during the quarter, leaving its top-line reliant on existing agreements like the $650M potential deal with Almirall (dermatology). This reliance on external funding highlights a key vulnerability: revenue volatility tied to partnership execution. | Metric | Q2 2025 Actual | Q2 2025 Forecast | Miss (%) | |----------------------------|-----------------|-------------------|----------| | Revenue | $600,000 | $1.39M | -56.83% | | Partner Program Revenue | $600,000 | $1.28M (TTM) | -53.3% | | Net Loss | $30.6M | $25.8M (TTM) | +18.6% | Query |code|stock code|stock name|Last Price|Last Change|Theme|Inclusion Reason|market_code| |---|---|---|---|---|---|---|---| |CANG|CANG.N|Cango|5.065|3.3673469999999996|||169| |CAN|CAN.O|Canaan|0.7645|1.488768|||185| |RIOT|RIOT.O|Riot Platforms|13.3449|0.945537|||186| |HUT|HUT.O|Hut 8|23.51|0.556269|||185| |BTDR|BTDR.O|Bitdeer|13.29|-0.449438|||186| |BTCM|BTCM.N|BIT Mining|3.11|-0.9554139999999999|||169| |BTBT|BTBT.O|Bit Digital|2.85|-1.041667|||186| |WULF|WULF.O|TeraWulf|8.965|-2.1834059999999997|||186| |BTOG|BTOG.O|Bit Origin|0.4733|-2.713258|||186| |CLSK|CLSK.O|CleanSpark|9.52|-3.105906|||186| #### **2. R&D Burn Rate Accelerates** Absci’s aggressive investment in its AI-driven drug creation platform drove R&D expenses to $20.5M (YoY +34%). This reflects progress in internally developed programs like ABS-101 (IBD) and ABS-201 (alopecia), but also raises concerns about cash utilization. The company’s cash reserves ($117.5M) provide a buffer, but the burn rate (~$30M/quarter) could pressure margins if revenue growth stalls. | Expense Category | Q2 2025 Actual | YoY Change | |----------------------------|-----------------|-------------| | R&D Expenses | $20.5M | +34% | | SG&A Expenses | $8.5M | -8.6% | | Total Expenses | $30.6M | +24% | #### **3. Pipeline Execution Risks** Absci’s pipeline remains in early stages: - **ABS-101** (anti-TL1A for IBD): Phase 1 interim data expected in late 2025. - **ABS-201** (anti-PRLR for alopecia): Preclinical data available, Phase 1 planned for early 2026. - **ABS-501** (anti-HER2 for oncology): Early-stage development. The long timeline to commercialization (2030+) means no near-term revenue from these programs, leaving Absci reliant on partnerships for cash flow. #### **4. Market Context: Biotech Volatility** The broader biotech sector faces headwinds, including regulatory scrutiny, funding constraints, and competition from AI-driven peers like Generate Biomedicines. Absci’s stock resilience (+4.39% post-earnings) suggests investor confidence in its AI platform, but the near-term financial risks remain significant. --- ### **Key Takeaways** - **Short-Term Risk**: Revenue volatility and high R&D burn rate. - **Long-Term Opportunity**: AI-driven pipeline targeting $14B markets (IBD, alopecia). - **Catalysts**: Phase 1 data for ABS-101 (late 2025), ABS-201 (2026), and potential partnerships. For investors, the trade-off is clear: tolerate near-term financial pain for a shot at disrupting AI-driven drug discovery.